LATEST RESEARCH
Investing in EU Biotech IP – What Works?
Vital Transformation released its newest research at the European Health Forum Gastein on October 4th, 2018. Our project analysed 116 EU biotech start-ups from the period of 2001 – 2007 through September 21, 2018 from the UK, Netherlands, Belgium, and Spain. We focused on companies developing medicinal products for human consumption. In this work, we compared the impact of IPOs (stock market listings), private investors, and direct EU funding on their success or failure.
MORE RESEARCH
-
DIA Global 2018: Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies GalleryDIA Global 2018: Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies
DIA Global 2018: Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies
24th June 2018, Boston, USA
Duane Schulthess, Managing Director of Vital Transformation, and Luca Pani, former Director General of the Italian Medicine's Agency and currently a Faculty Member at the University of Miami, will run a 3 hour and 15 minute Short Course outlining how best to harness RWE to better understand the price, value, and impact of next generation therapies.
Real world big data for clinical research and drug development
30th December, 2017
The objective of this paper is to identify the extent to which real world data (RWD) is being utilized, or could be utilized, at scale in drug development. Through screening peer-reviewed literature, we have cited specific examples where RWD can be used for biomarker discovery or validation, gaining a new understanding of a disease or disease associations, discovering new markers for patient stratification and targeted therapies, new markers for identifying persons with a disease, and pharmacovigilance.
Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation
21st October, 2015
After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is
beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the
guidance of the European Medicines Agency in 2014.
Report: The challenges and changes needed to reengineer medicines development in the UK
9th March, 2015
A new report from the ABPI and Vermilion Life Sciences examines the challenges and changes needed for the UK to lead reengineering medicines development, and proposes a new methodology to achieve this.